JP2016106075A - 抗ウィルス化合物 - Google Patents

抗ウィルス化合物 Download PDF

Info

Publication number
JP2016106075A
JP2016106075A JP2015212539A JP2015212539A JP2016106075A JP 2016106075 A JP2016106075 A JP 2016106075A JP 2015212539 A JP2015212539 A JP 2015212539A JP 2015212539 A JP2015212539 A JP 2015212539A JP 2016106075 A JP2016106075 A JP 2016106075A
Authority
JP
Japan
Prior art keywords
independently
substituted
membered
alkyl
case
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015212539A
Other languages
English (en)
Japanese (ja)
Inventor
デイビツド・エイ・デイゴーイ
David A Degoey
ウオーレン・エム・ケイテイ
Warren M Kati
チヤールズ・ダブリユ・ハツチンス
W Hutchins Charles
パメラ・エル・ドナー
Pamela L Donner
アラン・シー・クリユーガー
C Krueger Allan
ジヨン・テイー・ランドルフ
John T Randolph
クリストフアー・イー・モツター
Christopher E Motter
リサ・テイー・ネルソン
Lissa T Nelson
サツチエル・ブイ・パテル
V Patel Sachin
マーク・エイ・マツレンコ
Mark A Matulenko
ライアン・ジー・ケデイー
Ryan G Keddy
タミー・ケイ・ジンカーソン
K Jinkerson Tammie
イー・ガオ
Yi Gao
ダーチユン・リウ
Dachun Liu
ジヨン・ケイ・プラツト
John K Pratt
トツド・ダブリユ・ロツクウエイ
Todd W Rockway
クラレンス・ジエイ・マーリング
Clarence J Maring
ダグラス・ケイ・ハツチンソン
Douglas K Hutchinson
チヤールズ・エイ・フレンテ
Charles A Flentge
ロルフ・ワグナー
Rolf Wagner
マイケル・デイー・テユフアノ
Michael D Tufano
デイビツド・エイ・ベテベナー
David A Betebenner
キヤシー・サリス
Kathy Sarris
ケビン・アール・ウオーラー
R Woller Kevin
シーブル・エイチ・ワゴー
Sable H Wagaw
ジーン・シー・カリフアノ
C Califano Jean
ウエンケ・リー
Wenke Li
ダニエル・デイー・カスピ
D Caspi Daniel
メアリー・イー・ベリツツイ
Mary E Bellizzi
ウイリアム・エイ・キヤロル
A Carroll William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Bahamas Ltd
Original Assignee
AbbVie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/903,822 external-priority patent/US20110092415A1/en
Priority claimed from US13/100,827 external-priority patent/US8937150B2/en
Application filed by AbbVie Bahamas Ltd filed Critical AbbVie Bahamas Ltd
Publication of JP2016106075A publication Critical patent/JP2016106075A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015212539A 2010-10-13 2015-10-29 抗ウィルス化合物 Pending JP2016106075A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12/903,822 2010-10-13
US12/903,822 US20110092415A1 (en) 2009-06-11 2010-10-13 Anti-Viral Compounds
US12/964,027 2010-12-09
US12/964,027 US8921514B2 (en) 2009-06-11 2010-12-09 Anti-viral compounds
US201161446800P 2011-02-25 2011-02-25
US61/446,800 2011-02-25
US13/100,827 2011-05-04
US13/100,827 US8937150B2 (en) 2009-06-11 2011-05-04 Anti-viral compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013533986A Division JP5834085B2 (ja) 2010-10-13 2011-10-12 抗ウィルス化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017224527A Division JP6586147B2 (ja) 2010-10-13 2017-11-22 抗ウィルス化合物

Publications (1)

Publication Number Publication Date
JP2016106075A true JP2016106075A (ja) 2016-06-16

Family

ID=55069204

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015212539A Pending JP2016106075A (ja) 2010-10-13 2015-10-29 抗ウィルス化合物
JP2017224527A Active JP6586147B2 (ja) 2010-10-13 2017-11-22 抗ウィルス化合物
JP2019161909A Active JP6790202B2 (ja) 2010-10-13 2019-09-05 抗ウィルス化合物
JP2020183474A Pending JP2021035964A (ja) 2010-10-13 2020-11-02 抗ウィルス化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017224527A Active JP6586147B2 (ja) 2010-10-13 2017-11-22 抗ウィルス化合物
JP2019161909A Active JP6790202B2 (ja) 2010-10-13 2019-09-05 抗ウィルス化合物
JP2020183474A Pending JP2021035964A (ja) 2010-10-13 2020-11-02 抗ウィルス化合物

Country Status (18)

Country Link
JP (4) JP2016106075A (enExample)
KR (1) KR101990936B1 (enExample)
CA (1) CA2938547A1 (enExample)
CY (1) CY1117188T1 (enExample)
DK (1) DK2692346T3 (enExample)
ES (1) ES2560842T3 (enExample)
GT (1) GT201300093AA (enExample)
HR (1) HRP20151389T1 (enExample)
HU (1) HUE026832T2 (enExample)
IL (2) IL225010A (enExample)
ME (1) ME02328B (enExample)
MY (1) MY164064A (enExample)
PT (1) PT2692346E (enExample)
RS (1) RS54619B1 (enExample)
SI (1) SI2692346T1 (enExample)
TW (1) TWI621611B (enExample)
UA (1) UA113048C2 (enExample)
ZA (3) ZA201302269B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573503A (zh) * 2017-04-28 2019-12-13 圣提内尔肿瘤学有限公司 作为plk1抑制剂的吡咯衍生物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500324A (ja) * 1991-10-11 1995-01-12 デュポン・ファーマシュウティカルズ・カンパニー レトロウイルスプロテアーゼ阻害剤として有用な置換された環状カルボニルおよびその誘導体
JP2002508007A (ja) * 1997-07-09 2002-03-12 オントジエン・コーポレイシヨン Ｍｄｒモジュレーターとしてのイミダゾール誘導体
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP2010527373A (ja) * 2007-05-17 2010-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
JP2012529534A (ja) * 2009-06-11 2012-11-22 アボット・ラボラトリーズ Ｈｃｖ感染を治療するための抗ウィルス化合物
JP2014510063A (ja) * 2011-02-25 2014-04-24 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
JP5834085B2 (ja) * 2010-10-13 2015-12-16 アッヴィ・バハマズ・リミテッド 抗ウィルス化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500324A (ja) * 1991-10-11 1995-01-12 デュポン・ファーマシュウティカルズ・カンパニー レトロウイルスプロテアーゼ阻害剤として有用な置換された環状カルボニルおよびその誘導体
JP2002508007A (ja) * 1997-07-09 2002-03-12 オントジエン・コーポレイシヨン Ｍｄｒモジュレーターとしてのイミダゾール誘導体
JP2010527373A (ja) * 2007-05-17 2010-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP2012529534A (ja) * 2009-06-11 2012-11-22 アボット・ラボラトリーズ Ｈｃｖ感染を治療するための抗ウィルス化合物
JP5911838B2 (ja) * 2009-06-11 2016-04-27 アッヴィ・バハマズ・リミテッド Ｈｃｖ感染を治療するための抗ウィルス化合物
JP2016128456A (ja) * 2009-06-11 2016-07-14 アッヴィ・バハマズ・リミテッド Ｈｃｖ感染を治療するための抗ウィルス化合物
JP5834085B2 (ja) * 2010-10-13 2015-12-16 アッヴィ・バハマズ・リミテッド 抗ウィルス化合物
JP2014510063A (ja) * 2011-02-25 2014-04-24 アッヴィ・インコーポレイテッド 抗ウイルス性化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573503A (zh) * 2017-04-28 2019-12-13 圣提内尔肿瘤学有限公司 作为plk1抑制剂的吡咯衍生物
JP2020522465A (ja) * 2017-04-28 2020-07-30 センチネル オンコロジー リミテッド Ｐｌｋ１阻害剤としてのピロール誘導体
JP7189153B2 (ja) 2017-04-28 2022-12-13 センチネル オンコロジー リミテッド Ｐｌｋ１阻害剤としてのピロール誘導体
US11884656B2 (en) 2017-04-28 2024-01-30 Sentinel Oncology Limited Pyrrole derivatives as PLK1 inhibitors

Also Published As

Publication number Publication date
IL261206B (en) 2019-12-31
HUE026832T2 (en) 2016-07-28
CY1117188T1 (el) 2017-04-05
MY164064A (en) 2017-11-15
ZA201903284B (en) 2021-01-27
ZA201705519B (en) 2019-04-24
HRP20151389T1 (hr) 2016-01-15
PT2692346E (pt) 2016-03-22
JP2020059696A (ja) 2020-04-16
ZA201302269B (en) 2021-05-26
KR101990936B1 (ko) 2019-06-19
KR20180026775A (ko) 2018-03-13
DK2692346T3 (en) 2016-02-29
IL225010A (en) 2016-04-21
ES2560842T3 (es) 2016-02-23
JP2018065828A (ja) 2018-04-26
HK1188717A1 (en) 2014-05-16
JP2021035964A (ja) 2021-03-04
UA113048C2 (xx) 2016-12-12
JP6790202B2 (ja) 2020-11-25
IL261206A (en) 2018-10-31
CA2938547A1 (en) 2012-04-19
JP6586147B2 (ja) 2019-10-02
GT201300093AA (es) 2015-07-08
ME02328B (me) 2016-06-20
TW201412707A (zh) 2014-04-01
TWI621611B (zh) 2018-04-21
SI2692346T1 (sl) 2016-03-31
RS54619B1 (sr) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5834085B2 (ja) 抗ウィルス化合物
US8921514B2 (en) Anti-viral compounds
US20120220562A1 (en) Anti-Viral Compounds
JP6790202B2 (ja) 抗ウィルス化合物
AU2016238925B2 (en) Anti-viral compounds
US20230285378A1 (en) Anti-Viral Compounds
AU2014203655B2 (en) Anti-viral compounds
HK1188717B (en) An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative
HK1188987A (en) Anti-viral compounds
HK40004306A (en) Anti-viral compounds

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180130